Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
RPG Life Sciences Ltd (RPGLIFE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532983 NSE: RPGLIFE Pharmaceuticals & Drugs | Small Cap | RPG Life Sciences Share Price
₹2,694.75 -82.75 (-2.98%)
As on 11-Sep'26 16:59
RPG Life Sciences Ltd (RPGLIFE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532983 NSE: RPGLIFE Pharmaceuticals & Drugs | Small Cap | RPG Life Sciences Share Price
₹2,694.75 -82.75 (-2.98%)
As on 11-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹4,457 Cr.
Current Price
₹2,694.8
52-Week Low / High
₹1,731 / 3,081
TTM EPS
₹69.6
TTM Sales
₹708 Cr.
Book Value per Share
₹384.6
P/E Ratio
38.70
Higher than its 5-year historical median
Industry PE
54.2
Price to Book (P/B)
7.01
Higher than its 5-year historical median
Price to Sales (P/S)
6.30
Higher than its 5-year historical median
EV/EBITDA
24.69
Higher than its 5-year historical median
Dividend Yield
0.89%
Profitability Efficiency
Return on Equity (ROE)
20.28%
Outperforms industry median
Return on Capital Employed (ROCE)
26.99%
Outperforms industry median
Return on Assets (ROA)
15.89%
Operating Profit Margin
20.9%
Net Profit Margin
16.28%
Gross Profit Margin
22.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
8.28%
Operating Profit Growth (1 Year)
-
-6.92%
Net Profit Growth (1 Year)
-
-37.15%
Asset Quality
Promoter Holding
72.95%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹623 Cr.
Equity
₹13.2 Cr.
Face Value
₹8
All Time Low / High
₹17.10 / 3080.90
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is RPG Life Sciences Ltd a good quality company?
RPG Life Sciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does RPG Life Sciences Ltd performance compare with that of its Peers?
Revenue growth of RPG Life Sciences Ltd vs industry peers?
RPG Life Sciences Ltd revenue CAGR is 42.67%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of RPG Life Sciences Ltd?
Promoters hold 72.95% of the RPG Life Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of RPG Life Sciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 18.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
RPG Life Sciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 10.5% | 12.5% | 9.8% | 20.4% | 27.3% | 31.5% | 32.9% | 35% | 51.8% | 27% | - |
| Value Creation Index ⓘ | -0.3 | -0.1 | -0.3 | 0.5 | 1.0 | 1.3 | 1.4 | 1.5 | 2.7 | 0.9 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 708 | 734 |
| Sales YoY Gr. | - | 17.1% | -4% | 13.8% | 3.6% | 13.1% | 16.5% | 13.5% | 12.3% | 8.3% | - |
| Adj EPS ⓘ | 7.4 | 8 | 6.3 | 19.6 | 24 | 30.8 | 41 | 53 | 75.3 | 64.1 | 72.2 |
| YoY Gr. | - | 9% | -21.7% | 212.4% | 22.2% | 28.5% | 33% | 29.3% | 42% | -14.9% | - |
| BVPS (₹) ⓘ | 88.9 | 93.6 | 97.1 | 106.8 | 130.9 | 154.7 | 186 | 226.7 | 320.8 | 366.1 | 384.5 |
| Adj Net Profit ⓘ | 12.2 | 13.3 | 10.4 | 32.5 | 39.7 | 51 | 67.8 | 87.7 | 124 | 106 | 119 |
| Cash Flow from Ops. ⓘ | 7.3 | 14.7 | 45.8 | 50.2 | 58.3 | 64.8 | 90.8 | 94.4 | 77.9 | 56.5 | - |
| Debt/CF from Ops. ⓘ | 6.1 | 3.7 | 0.8 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 10.3% | 12.7% | 11.3% | 8.3% | ||||
| Adj EPS ⓘ | 27.2% | 21.7% | 16.1% | -14.9% | ||||
| BVPSⓘ | 17% | 22.8% | 25.3% | 14.1% | ||||
| Share Price | 18.2% | 34.1% | 29.1% | 14.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 8.7 | 8.8 | 6.6 | 19.3 | 20.2 | 21.6 | 24.1 | 25.7 | 27.5 | 18.7 | 19.2 |
| Op. Profit Mgn % ⓘ | 9.8 | 10.8 | 10.5 | 16 | 18.2 | 19.8 | 20.3 | 22.2 | 24.3 | 20.9 | 21.1 |
| Net Profit Mgn % ⓘ | 4.1 | 3.9 | 3.2 | 8.6 | 10.2 | 11.6 | 13.2 | 15.1 | 19.1 | 15 | 16.3 |
| Debt to Equity ⓘ | 0.3 | 0.4 | 0.2 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 123 | 113 | 122 | 105 | 118 | 105 | 97 | 96 | 98 | 120 | 127 |
| Cash Conv. Cycle ⓘ | 49 | 44 | 44 | 40 | 44 | 40 | 30 | 23 | 26 | 41 | 89 |
Valuation of RPG Life Sciences - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Sales | 653 | 708 |
| Operating Expenses ⓘ + | 494 | 560 |
| Operating Profit ⓘ | 159 | 148 |
| Operating Profit Margin (%) | 24.3% | 20.9% |
| Other Income ⓘ + | 14 | 26 |
| Interest ⓘ | 2 | 2 |
| Depreciation ⓘ | 21 | 21 |
| Profit Before Tax ⓘ | 233 | 154 |
| Tax ⓘ | 50 | 39 |
| Profit After Tax | 183 | 115 |
| PAT Margin (%) | 28.0% | 16.3% |
| Adjusted EPS (₹) | 110.8 | 69.6 |
| Dividend Payout Ratio (%) | 21.70% | 34.50% |
| PARTICULARS | Mar'25 | Mar'26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 531 | 605 | |||||||||
| Debt + | 0 | 13 | |||||||||
| Minority Interest | 0 | 0 | |||||||||
| Trade Payables | 79 | 97 | |||||||||
| Others Liabilities ⓘ | 47 | 77 | |||||||||
| Total Liabilities ⓘ | 657 | 793 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 172 | 197 | |||||||||
| CWIP ⓘ | 16 | 23 | |||||||||
| Investments ⓘ | 127 | 85 | |||||||||
| Inventories | 93 | 124 | |||||||||
| Trade Receivables | 87 | 117 | |||||||||
Cash Equivalents 
ⓘ
| 140 | 192 | |||||||||
| Others Assets ⓘ | 23 | 56 | |||||||||
| Total Assets ⓘ | 657 | 793 | |||||||||
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 78 | 57 |
| Cash Flow From Investing Activity ⓘ + | -42 | 86 |
| Cash Flow From Financing Activity ⓘ + | -27 | -21 |
| Net Cash Flow ⓘ | 9 | 122 |
| PARTICULARS | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 34.54 | 20.28 | ||||||||
| ROCE (%) | 44.2 | 26.99 | ||||||||
| Asset Turnover Ratio | 1.07 | 1.04 | ||||||||
| PAT to CFO Conversion(x) | 0.43 | 0.5 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 45.20 | 49.10 | ||||||||
| Inventory Days | 48.40 | 52.30 | ||||||||
| Payable Days | 147.40 | 138.20 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
RPG Life Sciences Ltd FAQs
The current trading price of RPG Life Sciences on 11-Sep-2026 16:59 is ₹2,694.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of RPG Life Sciences stood at ₹4,456.9 Cr
The latest P/E ratio of RPG Life Sciences as of 10-Sep-2026 is 37.31.
The latest P/B ratio of RPG Life Sciences as of 10-Sep-2026 is 7.01.
The 52-week high of RPG Life Sciences is ₹3,080.9 and the 52-week low is ₹1,731.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of RPG Life Sciences is ₹734 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that RPG Life Sciences Ltd is a average quality company.
The key valuation ratios of RPG Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of RPG Life Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About RPG Life Sciences Ltd
RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group
RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.
The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.
RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.
Major Activities of the Company:
- Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
- Pharmaceutical formulations & domestic marketing [SBU – II] and Fermentation & biotechnology [SBU – III].
Company’s Patnership:
It is represented in over thirty countries through strategic partnerships and joint ventures.
- Dossiers/DMF Europe, Canada
- Artificial Sweetner-UK
- NSAID-Europe
- Formulations - Asia, Canada, Europe.
Achievements:
- 8 processes patented granted,both in India and overseas
- First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
- One of the two manufacturers of Vitamin B12 in India
- R&D approved by Department of Science & Technology, Government of India.
- Only manufacturer of Spironolactone, by the fermentation route, in India.
- Marketing APIs and formulations catering to all key therapeutic areas across the world.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
